Jan. 28, 2014
/PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the
ACES/SEE Caribbean Eye Meeting (
January 31 to February 4, 2014
. Imprimis will continue its Go Dropless™ campaign (
), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.
Imprimis previously announced its plans to launch its proprietary ophthalmic sterile injectable compounded formulations during the first half of 2014. These therapies, designed for ophthalmic surgery patients, include a formulation combining triamcinolone acetonide and moxifloxacin hydrochloride. A similar combination adds the antibiotic vancomycin. Both of these drug formulations have been used by physicians during cataract surgeries and many other eye surgeries where there is inflammation and a chance for post-operative infection. Imprimis anticipates also offering a suite of lyophilized mydriatic drug formulations using either epinephrine or phenyepherine, both of which may be combined with lidocaine.
The Caribbean Eye Meeting attendance continues the strong momentum Imprimis has been building from previous meetings, including the American Academy of Ophthalmology in
New Orleans, Louisiana
and "Cataract Surgery: Telling It Like It Is" in
. The company has also held several Ophthalmic Advisory Board meetings with national thought leaders. Each of these events provides the opportunity to build relationships and gain valuable insight on the company's innovations and business model from the perspective of the cataract surgeons who participate.
For those interested in scheduling meetings with Imprimis at the ACES/SEE Caribbean Eye Meeting, please register at
As the company previously stated when it acquired the intellectual property for these formulations in
, the current treatment regimen for the prevention of post-cataract surgery complication is primarily a costly pre-operative and post-operative self-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive care giver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' uniquely designed drug formulations utilize a fourth generation quinolone therapy combined with inflammatory suppression which provide new choices for physicians to address and resolve the primary ocular complications of ophthalmic surgery: infection risk and post-operative inflammation.
Imprimis believes that its formulations may have broad application in ophthalmic surgery, including the multi-billion global cataract surgery drug market. The cataract surgery market continues to grow tremendously. According to
nearly 22 million cataract surgeries were performed globally in 2013. This growth is not only because of the expanding aging population, but because the age at which patients demand cataract surgery has lowered, shown in a study by Mayo Clinic, portending the ophthalmology drug market to reach
ABOUT IMPRIMIS PHARMACEUTICALS
-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations. Imprimis' patent-pending drug formulations are available today and are being prescribed by physicians. For more information, please visit
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis' ability to acquire, develop, commercialize and market new formulations and technologies, enter into strategic alliances and transactions, including arrangements with pharmacies, physicians and healthcare organizations, commercialize its formulations and technologies, obtain intellectual property protection for its assets, accurately estimate its expenses and cash burn and raise additional funds, as well as the success of additional research and development activities related to its formulations and technologies, the projected size of the potential market for its technologies and formulations, unexpected new data, safety and technical issues, regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at
. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
1. Market Scope 2013 Comprehensive Report on the Global Cataract Surgical Equipment Market